BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30899415)

  • 1. Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma.
    Hall BR; Cannon A; Thompson C; Santhamma B; Chavez-Riveros A; Bhatia R; Nair HB; Nickisch K; Batra SK; Kumar S
    Genes Cancer; 2019 Feb; 10(1-2):1-10. PubMed ID: 30899415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
    Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
    Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
    Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
    Tang W; Ramasamy K; Pillai SMA; Santhamma B; Konda S; Pitta Venkata P; Blankenship L; Liu J; Liu Z; Altwegg KA; Ebrahimi B; Pratap UP; Li X; Valente PT; Kost E; Sareddy GR; Vadlamudi RK; Nair HB; Tekmal RR; Viswanadhapalli S
    Cell Death Discov; 2021 Aug; 7(1):216. PubMed ID: 34400617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
    Ebrahimi B; Viswanadhapalli S; Pratap UP; Rahul G; Yang X; Pitta Venkata P; Drel V; Santhamma B; Konda S; Li X; Sanchez ALR; Yan H; Sareddy GR; Xu Z; Singh BB; Valente PT; Chen Y; Lai Z; Rao M; Kost ER; Curiel T; Tekmal RR; Nair HB; Vadlamudi RK
    NPJ Precis Oncol; 2024 May; 8(1):118. PubMed ID: 38789520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
    Blankenship L; Pratap UP; Yang X; Liu Z; Altwegg KA; Santhamma B; Ramasamy K; Konda S; Chen Y; Lai Z; Zheng S; Sareddy GR; Valente PT; Kost ER; Nair HB; Tekmal RR; Vadlamudi RK; Viswanadhapalli S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of an in vitro 3D PDAC stroma rich spheroid model.
    Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
    Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance.
    Lee JH; Kim SK; Khawar IA; Jeong SY; Chung S; Kuh HJ
    J Exp Clin Cancer Res; 2018 Jan; 37(1):4. PubMed ID: 29329547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.
    Tsai S; McOlash L; Palen K; Johnson B; Duris C; Yang Q; Dwinell MB; Hunt B; Evans DB; Gershan J; James MA
    BMC Cancer; 2018 Mar; 18(1):335. PubMed ID: 29587663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.
    Nielsen MF; Mortensen MB; Detlefsen S
    World J Gastroenterol; 2016 Mar; 22(9):2678-700. PubMed ID: 26973408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
    Kota J; Hancock J; Kwon J; Korc M
    Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies.
    Bahrami A; Khazaei M; Bagherieh F; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
    J Cell Physiol; 2017 Nov; 232(11):2931-2937. PubMed ID: 28083912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma.
    Koikawa K; Ohuchida K; Ando Y; Kibe S; Nakayama H; Takesue S; Endo S; Abe T; Okumura T; Iwamoto C; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Nagai E; Mizumoto K; Hashizume M; Nakamura M
    Cancer Lett; 2018 Jul; 425():65-77. PubMed ID: 29580808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer stroma: controversies and current insights.
    Ansari D; Carvajo M; Bauden M; Andersson R
    Scand J Gastroenterol; 2017; 52(6-7):641-646. PubMed ID: 28276831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
    Ernsting MJ; Hoang B; Lohse I; Undzys E; Cao P; Do T; Gill B; Pintilie M; Hedley D; Li SD
    J Control Release; 2015 May; 206():122-30. PubMed ID: 25804872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets.
    Farran B; Nagaraju GP
    Cytokine Growth Factor Rev; 2019 Aug; 48():11-23. PubMed ID: 31331827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance.
    Erkan M; Reiser-Erkan C; Michalski CW; Kong B; Esposito I; Friess H; Kleeff J
    Curr Mol Med; 2012 Mar; 12(3):288-303. PubMed ID: 22272725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Stroma in the Management of Pancreatic Cancer.
    Edwards P; Kang BW; Chau I
    Front Oncol; 2021; 11():691185. PubMed ID: 34336679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.
    Averett C; Bhardwaj A; Arora S; Srivastava SK; Khan MA; Ahmad A; Singh S; Carter JE; Khushman M; Singh AP
    Carcinogenesis; 2016 Nov; 37(11):1052-1061. PubMed ID: 27609457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Pancreatic Stellate Cells in Cancer.
    Schnittert J; Bansal R; Prakash J
    Trends Cancer; 2019 Feb; 5(2):128-142. PubMed ID: 30755305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.